A phase I study of ZIO-201-T [palifosfamide] in combination with doxorubicin in subjects with advanced, refractory solid tumors for which no standard therapy exists and for whom treatment with doxorubicin is considered medically acceptable.

Trial Profile

A phase I study of ZIO-201-T [palifosfamide] in combination with doxorubicin in subjects with advanced, refractory solid tumors for which no standard therapy exists and for whom treatment with doxorubicin is considered medically acceptable.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2013

At a glance

  • Drugs Palifosfamide (Primary) ; Doxorubicin
  • Indications Non-small cell lung cancer; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors ZIOPHARM Oncology
  • Most Recent Events

    • 18 Sep 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
    • 18 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Jun 2009 Results were presented at the 45th Annual American Society of Clinical Oncology (ASCO) meeting, according to a ZIOPHARM media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top